Document:

<PAGE>
                                                                    EXHIBIT 10.1

                               PURCHASE AGREEMENT

                                    RECITALS:

         Baxter Healthcare Corporation, a Delaware corporation, through its
BioScience business unit, with offices at 1627 Lake Cook Road, Deerfield,
Illinois 60015 ("Baxter") is extending to Coram, Inc., a Delaware corporation,
with offices at 1675 Broadway, #900, Denver, CO 80202 ("Customer") the following
pricing for the therapeutics ("Therapeutics ") set forth in Exhibit A. This
pricing is being offered to Customer in accordance with the terms and conditions
of this Therapeutics Purchase Agreement as well as the Terms and Conditions set
forth in Exhibit B (collectively, the Therapeutics Purchase Agreement, Exhibit A
and Exhibit B are referred to herein as the "Agreement"). Baxter and Customer
are collectively referred to herein as the "Parties".

         Baxter agrees to sell the Therapeutics to Customer and Customer agrees
to purchase the Therapeutics from Baxter for resale, distribution or use within
the United States, excluding commonwealths and possessions, to patients for whom
Customer holds an active prescription for the Therapeutics and/or to whom
Customer provides homecare services. Customer agrees to maintain all licenses
necessary for the purchase and dispensing of the prescription Therapeutics
(e.g., state pharmacy license, physician's license, etc.) and will forward a
copy of such license to Baxter upon request. The Therapeutics purchased under
this Agreement are not for resale, barter or trade to other purchasers of such
therapeutics and devices or for export without the prior written consent of
Baxter.

Now Therefore, It Is Hereby Agreed As Follows:

A.  TERM OF AGREEMENT

         Unless otherwise terminated as herein provided, the term of this
         Agreement shall be June 1, 2003 through December 31, 2003 ("Term of
         Agreement").

B. DELIVERY

         Freight terms are F.O.B. Customer's destination, Malvern, PA, freight
         pre-paid. Under normal conditions, shipment will be made within ten
         (10) business days of (i) June 2, 2003, and (ii) the date of Customer's
         request, both as more fully set forth in Section C. Customer agrees
         that all delivery dates specified in this Agreement are intended as
         target dates that Baxter will attempt in good faith to meet. Baxter
         may, however, attempt delivery either before or after the stated date
         as long as the date of delivery is not unreasonably disproportionate to
         the stated date. Seller shall invoice Customer for each lot as it is
         shipped.

C.  QUANTITY COMMITMENT

         The quantity commitment of Therapeutics that Customer has agreed to
         purchase is [        *         ]. For the Term of Agreement, Customer
         agrees to purchase and Baxter agrees to sell said quantity commitment
         of Therapeutics, to be delivered as follows: (i) [        *       ] on
         or about June 2, 2003, and (ii) [   *   ] as requested by Customer
         (subject to availability) but in no event later than December 30, 2003.

D. FAILURE TO DELIVER

         In the event Baxter fails to make delivery for any reason, other than
         Customer's termination of this Agreement without cause or a force
         majeure event (as described in Exhibit B), or Customer rightfully
         rejects or justifiably revokes acceptance, then with respect to the
         Therapeutic(s) involved, at Customer's option, Baxter shall either
         deliver or redeliver such Therapeutic(s) or Baxter shall pay Customer
         an amount equal to [                          *
                                             ] as liquidated damages, which
         figure shall include both incidental and consequential damages.

<PAGE>

E. FAILURE TO SATISFY QUANTITY COMMITMENT

         In the event Customer breaches this Agreement by failing to satisfy its
         Therapeutics quantity commitment set forth in Section C, for any reason
         other than Baxter's termination of this Agreement without cause or a
         force majeure event (as described in Exhibit B) then Customer shall pay
         to Baxter an amount equal to [                       *
                                  ] as liquidated damages, which figure shall
         include both incidental and consequential damages.

F. PRICING AND PAYMENT TERMS

         (1) The pricing set forth in Exhibit A shall remain firm during the
         term of this Agreement

         (2) Payment terms are [    *    ] from date of invoice. Customer shall
         pay Baxter a service charge of 1-1/2% per month, 18% per year (or the
         highest amount allowed by law, if lower) on all amounts past due
         pursuant to this Agreement. In the event Customer is delinquent in
         payment of any amounts due to Baxter, whether or not related to this
         Agreement, Baxter may, at its option, declare all amounts owed to it
         under all agreements as due and payable immediately and terminate this
         Agreement in accordance with the provisions of Section H(1) below.

G. ADDITIONAL SUPPLY

         If Customer's forecasted demand or subsequent request exceeds the
         quantity commitment set forth in Section C, subject to the terms of
         Section J and the paragraph entitled Force Majeure Event in Exhibit B,
         Baxter will use reasonable efforts to provide available Therapeutics to
         Customer to meet this excess forecasted demand or subsequent request in
         a fair and reasonable manner. Baxter will inform Customer as to whether
         it can fill the request for additional supply within seven (7) business
         days after Baxter's receipt of a written request from Customer for
         additional supply.

H. TERMINATION

         (1) TERMINATION WITHOUT CAUSE. Either Party shall have the right to
         terminate this Agreement upon thirty (30) days prior written notice to
         the other Party. However, in the event of any material breach of this
         Agreement by Customer, or in the case of any other action by Customer
         which Baxter deems prejudicial or injurious to the reputation of Baxter
         and/or the Therapeutics, which breach or action remains uncured after
         fifteen (15) days written notice by Baxter to Customer thereof, Baxter
         shall have the right to terminate this Agreement upon five (5) days
         prior written notice to Customer.

         (2) ORDERS PLACED PRIOR TO TERMINATION. In the event Baxter terminates
         this Agreement, at any time, with or without cause, under any
         circumstances whatsoever, Baxter, at its option, may cancel all
         unfilled orders of Customer for the Therapeutics outstanding as of the
         date on which the termination notice is given or this Agreement is
         automatically terminated.

         (3) CHANGE IN CONTROL. If Customer or any of its affiliates undergoes a
         Change in Control (as below defined), Customer will so notify Baxter in
         writing no more than five (5) business days after the date of
         occurrence of such event, and Baxter will have the right to terminate
         this Agreement effective with the Change in Control. "Change in
         Control" means the occurrence at any time of either of the following
         events:

                  (A)      Customer sells all or substantially all of its
                           business and/or assets to any entity; and/or

                  (B)      Any entity has become the beneficial owner (as the
                           term "beneficial owner" is defined under Rule 13d-3
                           of the Securities Exchange Act of 1934, as amended
                           (the "Exchange Act") and the rules and regulations
                           promulgated thereunder or any successor rule or
                           regulation promulgated under the Exchange Act) of 20%
                           or more of (i) the issued and outstanding shares of
                           voting securities or capital stock of Customer or
                           (ii) the equity interest of any other person or
                           entity which holds or controls any material part of
                           Customer's business and/or assets.

                                       2
<PAGE>
                  (C)      Notwithstanding the foregoing, for the purposes of
                           this Agreement, a "Change of Control" shall not
                           include any merger or other change of ownership of
                           Customer as a result of a Plan of Reorganization in
                           the Chapter 11 case of Customer and Coram Healthcare
                           Corporation currently pending in the United States
                           Bankruptcy Court for the District of Delaware (Case
                           No. 00-3299).

I.  CONFIDENTIALITY

         Neither Customer nor Baxter shall disclose the terms of this Agreement
         to any other person or entity outside its organization and affiliates,
         except to its business and legal advisors, other than as required by
         law. For purposes of this provision, an affiliate is an entity in which
         Customer or Baxter, as appropriate, maintains an ownership position in
         or a contractual relationship with, and the disclosure is required so
         that the disclosing Party may fulfill its obligations hereunder.
         Neither Party shall make any public announcement concerning the
         existence of this Agreement or its terms unless such Party receives the
         prior written approval of the other Party.

J. FORECAST

         Within thirty (30) days prior to each succeeding calendar quarter,
         Customer will provide Baxter with a written forecast of its anticipated
         purchases of the Therapeutic for the next calendar quarter of this
         Agreement. Baxter will use such forecast submitted by Customer in
         planning, provided, however, that in no event will any such forecast
         hereunder constitute an order, create any right or expectation in
         Customer or be binding in any respect upon Baxter or Customer.

K. TRACE SALES REPORTS

         On all purchases from Baxter, Customer agrees to maintain complete and
         accurate records of the sales of all Baxter Therapeutics covered under
         this Agreement. Customer agrees to provide monthly trace sales reports,
         to include the following information:

         o     Aggregate, de-identified patient information

         o     City, state and zip code of the prescribing physician

         o     Number of units, unit of measure, Baxter item code or NDC number
               and ship date

         THE ABOVE INFORMATION MUST BE RECEIVED WITHIN THREE (3) BUSINESS DAYS
         FOLLOWING THE LAST DAY OF EACH CALENDAR MONTH. The preferred format is
         Microsoft Excel spreadsheet sent electronically to the Baxter contact
         listed below.

Baxter spreadsheet information contact:     Customer contact information:
       Stephanie Felinczak             Name: Leo Gianacopoulos, Director of
  Stephanie_felinczak@baxter.com             Operations
       1627 Lake Cook Road             Email: gianacopoulosl@coramhc.com
       Deerfield, IL 60015             Address: Coram Hemophilia Services
       Ph# 847.948.6602                         6 Spring Mill Drive, Malvern, PA
       Fax# 847.940.5960                        19355
                                       Ph #
                                       Fax # (610) 578-1698

L.  INSURANCE

         Baxter shall secure and maintain insurance or self-insurance in any
         combination at Baxter's sole discretion in the amounts and types listed
         in this Section throughout the Term of Agreement at no expense to
         Customer. All insurance required in this Section shall list Customer as
         an additional insured. Underwriters shall endeavor to provide at least
         thirty (30) days notice of cancellation or non-renewal; however,
         failure to do so shall impose no penalty or obligation. Baxter shall
         maintain, with any combination of primary and umbrella insurance,
         commercial general liability insurance including Products/Completed
         Operations, Blanket Contractual Liability, and Personal/Advertising not
         less than [                       *                          ].

         Baxter shall maintain workers' compensation coverage and employer's
         liability insurance covering Baxter and all of Baxter's employees who
         enter Customer's premises for purposes of carrying out the transactions
         contemplated under this Agreement, in amounts not less than [
               *                     ]

                                       3
<PAGE>
         [
                                              *
                                                  ]. Workers' compensation
         coverage shall be in the form of a workers' compensation policy, and a
         health benefits policy shall not be deemed to comply with the
         requirements of this Section.

         Baxter and Customer each agree to waive all right of subrogation
         against the other, each other's agents, officers, employees, insurers
         and representatives.

M.  COMPLETE AGREEMENT

         This Agreement contains the full and complete expression of the rights
         and obligations of the Parties, and it shall supersede all other
         written or oral communications heretofore made by the Parties related
         to the subject matter hereof.

         IN WITNESS WHEREOF, the Parties have caused this Agreement to be
executed by their duly authorized representatives:

Coram, Inc.                                   Baxter Healthcare Corporation
                                              through its BioScience Division
                                              Sales and Marketing North America
                                              Region

By:  /s/ FRANK GEIGER                         By:    /s/ PETER O MALLEY
    ----------------------------------            -----------------------------

Name:    Frank Geiger                         Name:   Peter O Malley
      --------------------------------              ---------------------------
         Authorized Representative                   Authorized Representative

Title: Senior Vice President, MM              Title:  President
       -------------------------------               --------------------------

Date:   May 29, 2003                          Date:   May 29, 2003
      --------------------------------               --------------------------

                                       4
<PAGE>
                                    EXHIBIT A
                                       TO
                               PURCHASE AGREEMENT

            THERAPEUTIC DESCRIPTION, PRICING AND QUANTITY COMMITMENT
              FOR THE PERIOD JUNE 2, 2003 THROUGH DECEMBER 31, 2003

<Table>
<Caption>
                                                                                        BALANCE OF
                                                                      JUNE 2, 2003         2003
ALPHA(1) - PROTEINASE                                                   QUANTITY         QUANTITY
 INHIBITOR (HUMAN)            ITEM DESCRIPTION         PRICE/UNIT      COMMITMENT       COMMITMENT
---------------------         ----------------         ----------     ------------      ----------
<S>                           <C>                      <C>            <C>               <C>
Aralast 580100                25mL/0.5g vial            [  *   ]
NDC# - 49669-5800-1                                                       [  *  ]        [   *   ]
Aralast 580200                50mL/1.0g vial            [  *   ]       [   *    ]       [   *    ]
NDC# - 49669-5800-2
</Table>

Aralast is a trademark of Alpha Therapeutic Corporation

                                       5
<PAGE>

                                    EXHIBIT B
                                       TO
                               PURCHASE AGREEMENT

                              TERMS AND CONDITIONS

TAXES

Customer shall be responsible for payment of all applicable state and/or local
sales, use, and/or gross receipts tax receipts resulting from transactions with
Baxter regardless of placement of liability for the tax by law.

ORDERING PROCEDURE

Orders may be placed by calling Baxter Customer Service at 800.423.2090 or faxed
to 800.756.4952. Shipment against any purchase order does not constitute
acceptance by Baxter of the terms and conditions or prices stipulated on the
purchase order. Shipment of any order, including standing orders, will be made
in accordance with terms, conditions and prices in effect, as stated herein, and
shall be governed solely by the terms of the Agreement notwithstanding any
conflicting or additional terms contained in any purchase order, unless
otherwise agreed to in writing by the Parties. Baxter cannot guarantee maximum
Therapeutic expiration dating on any Therapeutics upon delivery. Specific dating
needs may be discussed with Customer Service at time of order placement.

SHIPPING INFORMATION

Additional charges for emergency or overnight deliveries will be the
responsibility of Customer and will be added to the invoice. DISPUTED INVOICES:
An amount in dispute should be deducted from Customer's remittance. PLEASE
EXPLAIN THE DEDUCTION ON A LEGIBLE COPY OF THE INVOICE AND ENCLOSE IT WITH THE
PAYMENT. Baxter's Account Services Representative will work with Customer to
resolve the discrepancy. DAMAGE OR SHORTAGE IN SHIPMENT: Baxter exercises
extreme care in packing shipments. To minimize the possibility of error, all
orders should be counted and inspected prior to acceptance of delivery from the
carrier. ANY DAMAGE, SHORTAGE OR OVERAGE SHOULD BE NOTED ON A COPY OF THE
CARRIER'S FREIGHT BILL AND THE DRIVER SHOULD COUNTERSIGN THE DOCUMENT. If the
damage is excessive do not accept the shipment. Mark on the carrier's freight
bill, "Shipment refused, damaged. Return to shipper." Baxter's Customer Service
Department should be notified immediately at 1-800-423-2090. Customer's
cooperation in providing this information will enable Baxter to expedite the
necessary adjustments. PROOF OF DELIVERY: Proof of delivery will be provided if
a request is received within ninety (90) days of date of shipment. Due to the
expenses involved in obtaining proof of delivery, requests are subject to a
$40.00 service fee. In the event that proof of delivery cannot be provided, no
service fee will be charged and full credit will be issued to Customer's
account.

FORCE MAJEURE EVENT

Each Party shall use commercially reasonable efforts to perform its obligations
under this Agreement, but shall not be liable for non-performance or delays
caused by a shortage of supply of raw materials, failure of supply,
manufacturing problems, delivery or labor problems, intervention of any
governmental authority or acts of regulatory agencies, fires, earthquakes, acts
of God or causes beyond its control. The non-performing Party will be excused
from performance for the duration of such events, will promptly notify the other
Party of the reasons for nonperformance and will diligently and continuously
attempt to resume its performance. Customer agrees that in such events Baxter,
without liability may allocate Therapeutics amongst its Customers in a fair and
reasonable manner. Baxter's available supply will be made available on a
pro-rata basis to customers with firm commitments. In the event Baxter is
notified of and is able to verify a decision which changes the purchase and
delivery of Therapeutics for a patient or a group of patients either to or from
Customer, then to the extent it is able, Baxter may have to make appropriate
adjustments in the supply of Therapeutics provided to Customer.

RETURN GOODS POLICY

Baxter can accept for credit only those Therapeutics that do not perform
satisfactorily under the specified condition, Therapeutics which may have been
damaged during transportation, or Therapeutics which Customer may have received
in error. Due to the biological nature of the Therapeutics and the government
regulations involved, return of the Therapeutics must be authorized before any
returns will be accepted. Customer shall contact Baxter Customer Service for
instructions on the return procedure to be followed.

WARRANTY

Baxter Healthcare Corporation and its affiliates warrant that the Therapeutics
shipped or delivered to Customer will not, at the time of shipment by Baxter or
its affiliates, be adulterated or misbranded within the meaning of the Federal
Food, Drug and Cosmetic Act, as amended. Baxter and its affiliates further
represent and warrant that all Therapeutics delivered to Customer have been
manufactured, processed, packed, filled and finished in substantial conformance
with cGMPs as set forth in 21 C.F.R. Parts 210 and 211 and are fit for the
purpose and indications described on the labeling. Unless the Therapeutic is
used in accordance with its instructions, these warranties are void and of no
effect. THERE ARE NO OTHER EXPRESS OR IMPLIED WARRANTIES, INCLUDING ANY WARRANTY
OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. BAXTER AND ITS
AFFILIATES' SOLE OBLIGATION AND CUSTOMER'S EXCLUSIVE REMEDY FOR BREACH OF ANY
WARRANTY SHALL BE, AT BAXTER'S OPTION, TO REPAIR OR REPLACE THE THERAPEUTIC.
NEITHER BAXTER NOR ITS AFFILIATES SHALL BE LIABLE FOR PROXIMATE, INCIDENTAL,
CONSEQUENTIAL OR EXEMPLARY DAMAGES.

OTHER DISCOUNTS

Customer acknowledges the dollar value of any Therapeutic which Customer
receives but does not pay for shall be a "discount or other reduction in price"
and may be subject to the disclosure requirements of Section 1128(b)(3)(A) of
the Social Security Act. Customer shall disclose this discount or reduction in
price under any state or federal program that provides cost or charge-based
reimbursement to the participating institution for the Therapeutic covered in
this price list.

                                       6<PAGE>

                                                                    EXHIBIT 10.2

                     SETTLEMENT AGREEMENT AND MUTUAL RELEASE

         This Settlement Agreement and Mutual Release ("Settlement Agreement")
is made and entered into as of this 2nd day of May, 2003 by and among HOBART G.
TRUESDELL, in his capacity as Chief Restructuring Officer of Coram Resource
Network, Inc. and Coram Independent Practice Association, Inc. ("TRUESDELL"),
CORAM RESOURCE NETWORK, INC., a Delaware corporation ("CRN"), CORAM INDEPENDENT
PRACTICE ASSOCIATION, INC., a New York corporation ("CIPA" and together with
CRN, collectively referred as "R-NET"), the OFFICIAL COMMITTEE OF UNSECURED
CREDITORS OF CORAM RESOURCE NETWORK, INC. AND CORAM INDEPENDENT PRACTICE
ASSOCIATION, INC. (the "R-NET COMMITTEE"), ARLIN M. ADAMS, in his capacity as
Chapter 11 Trustee For the Bankruptcy Estates of Coram Healthcare Corporation
and Coram, Inc. ("TRUSTEE"), CORAM HEALTHCARE CORP., a Delaware corporation
("CHC"), and CORAM, INC., a Delaware corporation ("CI" and together with CHC,
collectively referred to as "CORAM") and is made with reference to the
following:

RECITALS

         A. WHEREAS, CRN and CIPA are direct or indirect wholly-owned
subsidiaries of CORAM;

         B. WHEREAS, on August 19, 1999, a small group of creditors commenced an
involuntary bankruptcy case against CRN pursuant to Section 303 of Title 11 of
the United States Code Sections 101, et. seq. (the "Bankruptcy Code") in the
United States Bankruptcy Court for the District of Delaware (the "Bankruptcy
Court");

         C. WHEREAS, on November 12, 1999, CRN consented to the involuntary
bankruptcy filing, and, together with CIPA, filed voluntary petitions for relief
under Chapter 11 of the Bankruptcy Code;

         D. WHEREAS, R-NET's bankruptcy cases (the "R-NET Bankruptcy Cases")
were consolidated for administrative purposes and are now pending in the
Bankruptcy Court under the docket of In re Coram Resource Network Inc. and Coram
Independent Practice Association, Inc., Case No. 99-2889 (MFW);

         E. WHEREAS, on November 23, 1999, the R-NET COMMITTEE was appointed;

         F. WHEREAS, on December 6, 1999, Hobart G. Truesdell was appointed by
the Bankruptcy Court as R-NET's Chief Liquidating Officer;

         G. WHEREAS, in March of 2000, CHC, together with certain affiliates,
filed proofs of claim in the R-NET Bankruptcy Cases totaling $49,426,856.89 (the
"CORAM Claim") representing the net amount due to CORAM from R-NET from 1995
through 1999 for: (a) services provided to CRN by CHC and its affiliates, (b)
inter-company receivables owed to CHC for expenses paid by CHC on behalf of CRN;
and (c) repayments on a letter of credit made on

<PAGE>

behalf of R-NET (the CORAM Claim is net of a credit of $207,100,175 for cash
received by CHC on behalf of R-NET);

         H. WHEREAS, the R-NET COMMITTEE objected to CHC's proofs of claim;

         I. WHEREAS, on or about August 8, 2000, CORAM commenced two bankruptcy
cases (the "CORAM Bankruptcy Cases") by filing petitions for relief under
Chapter 11 of the Bankruptcy Code in the Bankruptcy Court;

         J. WHEREAS, the CORAM Bankruptcy Cases were consolidated for
administrative purposes and are now pending in the Bankruptcy Court under the
docket of In re Coram Healthcare Corp. and Coram, Inc., Case No. 00-3299 (MFW);

         K. WHEREAS, in September of 2000, R-NET filed four proofs of claim
against CORAM seeking $41,524,000.00 on the basis of an alleged agreement by
CORAM to reimburse R-NET for services provided by R-NET in connection with an
agreement with Aetna U.S. Healthcare (the "R-NET Reimbursement Claim");

         L. WHEREAS, also in September of 2000, R-NET filed three additional
proofs of claim for any and all other claims or causes of action arising in law,
equity or otherwise which may be raised by R-NET (together with R-NET
Reimbursement Claim, the "R-NET Claims");

         M. WHEREAS, on September 5, 2001, by Stipulation and Order Assigning to
Committee the Right to Pursue Certain Claims on Behalf of the Estate, the
Bankruptcy Court approved R-NET's assignment of the R-NET Claims to the R-NET
COMMITTEE;

         N. WHEREAS, the entire basis for the R-NET Claims is the allegations
made in that adversary proceeding filed in the R-Net Bankruptcy Cases on
November 13, 2001 (the "Adversary Proceeding") styled Official Committee of
Unsecured Creditors of Coram Resource Network, Inc. and Coram Independent
Practice Association, Inc. v. Coram Healthcare Corp., et al., Adv. Proc. No.
01-08795, and pending in the United States District Court for the District of
Delaware (the "District Court") under Case No. 03-CV-34.

         O. WHEREAS, on or about May 31, 2000, R-NET filed the Liquidating
Chapter 11 Plan of Coram Resource Network, Inc. and Coram Independent Practice
Association, Inc. together with an accompanying disclosure statement;

         P. WHEREAS, on October 21, 2002 the R-NET COMMITTEE filed the
Liquidating Chapter 11 Plan as Modified Proposed by the Official Committee of
Unsecured Creditors of Coram Resource Network, Inc., and Coram Independent
Practice Association and accompanying disclosure statement;

         Q. WHEREAS, the TRUSTEE has objected to the R-NET COMMITTEE's
disclosure statement;

                                       2

<PAGE>

         R. WHEREAS, on May 2, 2003, the TRUSTEE filed the Chapter 11 Trustee's
Joint Plan of Reorganization (the "TRUSTEE's Plan") and accompanying disclosure
statement which provides for, inter alia, approval of the Settlement Agreement;

         S. WHEREAS, the parties to this Settlement Agreement (individually and
collectively referred to as the "Parties") desire to fully and completely
resolve any and all disputes that have been raised or could be raised between
them concerning the CORAM Claims and the R-NET Claims, including, without
limitation, all claims raised in the Adversary Proceeding.

         NOW, THEREFORE, in consideration of the mutual promises, covenants, and
agreements set forth herein, and subject to the terms and conditions set forth
below, and intending to be legally bound hereby, TRUESDELL, R-NET, the R-NET
COMMITTEE, CORAM and the TRUSTEE agree as follows:

         1. Claims.

                  a. R-NET's general unsecured claim against CORAM shall be
fixed and allowed in the total amount of seven million nine hundred fifty
thousand dollars ($7,950,000.00) (the "R-NET Settlement Amount").

                  b. CORAM's general unsecured claims against R-NET shall be
fixed and allowed in the total amount of one thousand dollars ($1,000.00) per
proof of claim filed (the "CORAM Settlement Amount") and distributed in
accordance with the terms set forth in any plan of reorganization confirmed in
the R-NET Bankruptcy Cases.

         2. Agreements of the Parties. TRUESDELL, R-NET, the R-NET COMMITTEE,
CORAM and the TRUSTEE acknowledge and agree to the following terms and
conditions:

                  a. The TRUSTEE's Plan provides for a pro rata distribution to
holders of allowed general unsecured claims equal to one hundred cents on the
dollar (without post-petition interest), and provides for a possible
distribution on account of interest accruing (at the applicable federal judgment
rate) from CORAM's bankruptcy petition date through the effective date of the
TRUSTEE's Plan.

                  b. The TRUSTEE, TRUESDELL, R-NET and the R-NET COMMITTEE agree
to use their best efforts to obtain approval of this Agreement in the CORAM
BANKRUPTCY CASES through confirmation of the Trustee's Plan in accordance with
the Bankruptcy Code as soon as practicable.

                  c. The TRUSTEE, TRUESDELL, R-NET and the R-NET COMMITTEE agree
to use their best efforts to obtain approval of this Agreement in the R-NET
Bankruptcy Cases as soon as practicable.

                                       3

<PAGE>

                  d. The TRUSTEE shall undertake his best efforts to resolve the
priority tax claim(s) asserted by the Internal Revenue Service ("IRS") against
R-NET as a result of the Statutory Notice of Deficiency in the aggregate amount
of $12,670,543.00, plus interest, for the tax years ended September 30, 1987,
September 30, 1988, September 30, 1989, September 30, 1990 and September 30,
1991, issued on or about May 14, 1999, to T2 Medical, Inc., a CI subsidiary (the
"Tax Claim").

         3. Conditions Precedent. The parties hereby acknowledge and agree to
the following conditions precedent to the dismissal of the Adversary Proceeding
and the granting of mutual releases:

                  a. This Agreement is approved in the CORAM Bankruptcy Cases
through confirmation of the Trustee's Plan (as may be modified, amended or
supplemented from time to time), or any other substantially similar plan
proposed by or supported by the Trustee;

                  b. This Agreement is approved in the R-NET Bankruptcy Cases;
and

                  c. The IRS withdraws the Tax Claim, the Tax Claim is expunged
and/or the Tax Claim is resolved without any payment being required from
TRUESDELL or R-NET.

         4. Dismissal and Release. Upon the satisfaction of all of the
conditions precedent set forth in paragraph 3 above:

                  a. The R-NET COMMITTEE shall cause the Adversary Proceeding to
be dismissed with prejudice;

                  b. TRUESDELL, R-NET and the R-NET COMMITTEE shall release and
forever discharge (i) the TRUSTEE and each of his agents, heirs, successors in
interest, assigns and attorneys, and (ii) CORAM and each of their respective
past and present officers, directors, shareholders, employees, agents,
predecessors, successors in interest, assigns, attorneys, parent companies,
companies in common ownership, subsidiaries, lenders (and principals of
lenders), and affiliates and each of them (including but not limited to Donald
J. Amaral, Steven A. Feinberg, Joseph D. Smith, James Glynn, Peter (Perry)
Bernocchi, L. Peter Smith, Richard M. Smith, Scott Larson, Vito Ponzio, Kara
Strickler Anderson, Wendy L. Simpson, Robyn Hansen, Scott Danitz), Cerberus
Partners, L.P., Goldman Sachs Credit Partners, L.P., Foothill Capital
Corporation and Foothill Income Trust, L.P., from any and all claims, debts,
liabilities, demands, obligations, promises, acts, agreements, accountings,
costs and expenses (including, but not limited to, attorneys' fees and costs),
damages, liens, judgments, actions and causes of action of every kind and nature
whatsoever, at law or in equity, known or unknown, suspected or unsuspected, ,
including but not limited to the Adversary Proceeding, which TRUESDELL, R-NET
and/or the R-NET COMMITTEE ever had, now has, and may in the future have,
relating to or arising out of the R-NET Claims and occurring from the beginning
of time to the date of this Settlement Agreement.

                  c. The TRUSTEE and CORAM shall release and forever discharge
(i) TRUESDELL and each of his agents, heirs, successors in interest, assigns and
attorneys, (ii) the

                                       4

<PAGE>

R-NET COMMITTEE and each of its agents, successors in interest, assigns and
attorneys, and (iii) R-NET and each of their respective past and present
officers, directors, shareholders, employees, agents, predecessors, successors
in interest, assigns, attorneys, parent companies, companies in common
ownership, subsidiaries, and affiliates and each of them, from any and all
claims, debts, liabilities, demands, obligations, promises, acts, agreements,
accountings, costs and expenses (including, but not limited to, attorneys' fees
and costs), damages, liens, judgments, actions and causes of action of every
kind and nature whatsoever, at law or in equity, known or unknown, suspected or
unsuspected, which CORAM and/or the TRUSTEE ever had or now has, and may in the
future have, relating to or arising out of the Coram Claims and occurring from
the beginning of time to the date of this Settlement Agreement.

         5. Representations and Warranties.

                  a. Each of the Parties hereto represents and warrants that
they have carefully read this Settlement Agreement, the contents hereof are
known to them, and that this Settlement Agreement is executed voluntarily and
without duress or undue influence.

                  b. Each of the Parties hereto represents and warrants that in
executing this Settlement Agreement they rely solely upon their own judgment,
belief, and knowledge, and on the advice and recommendations of their own
independently selected counsel, concerning the nature, extent, and duration of
their rights and claims, and that they have not been influenced to any extent
whatsoever in executing this Settlement Agreement by any representations or
statements covering any matters made by any of the Parties or by any person
representing them or any of them.

                  c. Each of the Parties hereto represents and warrants that the
persons and entities executing this Settlement Agreement have the legal
authority to do so.

         6. Acknowledgements by the Parties.

                  a. Upon receipt of the settlement amounts referenced in
Paragraph 1 above in the manner and method contemplated herein, THE TRUSTEE,
TRUESDELL, R-NET and the R-NET COMMITTEE each acknowledge and agree that they
have knowingly relinquished, waived and released any and all remedies that might
otherwise be available to them for the matters or transactions that are the
subject of this Settlement Agreement.

                  b. It is further acknowledged and agreed that this Settlement
Agreement is a compromise of disputed claims, and that the exchange of
consideration contemplated herein is not to be construed as an admission of
liability on the part of the Parties hereby released.

         7. Applicable Law. This Settlement Agreement shall in all respects be
interpreted, enforced and governed by the laws of the State of Delaware,
disregarding Delaware's conflicts of law principles.

                                       5

<PAGE>

         8. Construction of Agreement.

                  a. This Settlement Agreement shall be construed as a whole
according to its fair meaning and as if all the Parties hereto had jointly
prepared this Settlement Agreement.

                  b. Whenever from the context it is appropriate, each term,
whether stated in the singular or the plural, will include both the singular and
the plural.

                  c. Each pronoun stated in the masculine, feminine or neuter
includes the masculine, feminine and neuter.

                  d. The words "herein," "hereunder" and "hereto" refer to this
Settlement Agreement in its entirety rather than to a particular portion of this
Settlement Agreement.

                  e. Captions and headings in this Settlement Agreement are
inserted for convenience of reference only and are not intended to be a part of,
or to affect the interpretation of, this Settlement Agreement.

         9. Binding on Parties. This Settlement Agreement shall be binding upon
and inure to the benefit of the Parties and their respective heirs,
representatives, successors, and assigns and each and every entity which now or
ever was a division, parent, successor, predecessor, or subsidiary for any of
the parties and/or their respective legal successors and assigns. In the event
that the conditions precedent set forth in paragraph 4 above are not satisfied,
each party shall be entitled to pursue any available claims, remedies or causes
of action, in law or in equity, against the other party as if this Settlement
Agreement did not exist.

         10. No Assignment. Except as otherwise specifically acknowledged in
Recital M above, the Parties, and each of them, mutually acknowledge that they
have not assigned to any person or entity all or any portion of any claim(s)
released herein.

         11. Severability. In the event that any covenant, condition or other
provision contained in this Settlement Agreement is held to be invalid, void or
illegal by any court of competent jurisdiction, the covenant, condition, or
other provision shall be deemed severable from the remainder of this Settlement
Agreement and shall in no way affect, impair or invalidate any other covenant,
condition or other provision. If any covenant, condition, or other provision
shall be deemed invalid due to its scope or breadth, the covenant, condition or
other provision shall be deemed valid to the extent of the scope or breadth
permitted by law.

         12. Waiver. A breach of any provision of this Settlement Agreement can
be waived only by a writing signed by the non-breaching party. Waiver of any one
breach of any provision hereof shall not be deemed to be a waiver of any other
breach of such provision or any other provision hereof.

         13 Amendments. This Settlement Agreement may be amended only by a
written agreement executed by the Parties.

                                       6

<PAGE>

         14. Entire Agreement. This Settlement Agreement constitutes the entire
agreement between or among the Parties pertaining to the subject matter hereof,
and there are no terms other than those contained herein. Any prior writing or
agreement previously between the Parties and/or any of their affiliates or
subsidiaries is superceded by this Agreement and shall be of no force and
effect.

         15. Further Action. The parties hereto agree to execute promptly upon
request any and all other documents and instruments necessary to effectuate the
terms of this Settlement Agreement.

         16. Counterparts. This Settlement Agreement may be executed in
counterparts and by facsimile and when each of the Parties has signed and
delivered at least one such counterpart, each counterpart shall be deemed an
original, and all counterparts taken together shall constitute one and the same
agreement, which shall be binding and effective as to all Parties.

         17. Notices. All notices, claims, demands, and other communications
hereunder shall be in writing and shall be delivered by facsimile transmission
and overnight mail, addressed to the respective parties at the following
addresses (or at such other address for a party as specified by notice under
this Paragraph):

                  If to CORAM:

                           Arlin M. Adams, Chapter 11 Trustee
                           Schnader Harrison Segal & Lewis LLP
                           1600 Market Street, Suite 3600
                           Philadelphia, PA  19103

                  with a copy to:

                           Barry E. Bressler, Esquire
                           Schnader Harrison Segal & Lewis LLP
                           1600 Market Street, Suite 3600
                           Philadelphia, PA  19103

                  If to R-NET:

                           Hobart G. Truesdell,
                            Chief Restructuring Officer of R-Net
                           C/o Walker Truesdell & Associates
                           380 Lexington Ave. - Suite 1514
                           New York, NY  10768

                  with a copy to:

                           Edwin J. Harron, Esquire
                           Young Conaway Stargatt & Taylor, LLP

                                       7

<PAGE>

                           The Brandywine Building
                           1000 West Street, 17th Floor
                           P.O. Box 391
                           Wilmington, DE  19899-0391

                  If to R-NET COMMITTEE:

                           Scott Shafer
                           Official Committee of Unsecured Creditors of R-Net
                           c/o Bayada Nurses, Inc.
                           101 Executive Drive
                           Moorestown, NJ  08057

                           with a copy to:

                           Lawrence J. Tabas, Esquire
                           Obermayer Rebmann Maxwell & Hippel, LLP
                           One Penn Center, 19th Floor
                           1617 John F. Kennedy Boulevard
                           Philadelphia, PA  19103-1895

         18. Bankruptcy Court Approval. This Settlement Agreement is subject to
approval by the Bankruptcy Court in both the CORAM Bankruptcy Cases and the
R-NET Bankruptcy Cases. The parties irrevocably consent to the jurisdiction of
the Bankruptcy Court with respect to any action to approve and enforce the terms
and provisions of this Settlement Agreement and expressly waives any right to
commence any such action in any other forum or to contest the jurisdiction of
the Bankruptcy Court.

         IN WITNESS WHEREOF, the Parties hereto have executed this Settlement
Agreement, effective as of the date first written above.

                                       8

<PAGE>

<Table>
<S>                                                          <C>
HOBART G. TRUESDELL                                          CORAM INDEPENDENT PRACTICE
                                                             ASSOCIATION, INC.

/s/ HOBART G. TRUESDELL                                      By: /s/ HOBART G. TRUESDELL
--------------------------------------------                    --------------------------------------------
Hobart G. Truesdell,                                            Hobart G. Truesdell,
Chief Restructuring Officer                                     Chief Restructuring Officer
Coram Resource Network, Inc. and                                Coram Resource Network, Inc. and Coram
Coram Independent Practice Association, Inc.                    Independent Practice Association, Inc.

THE OFFICIAL COMMITTEE OF                                    CORAM RESOURCE NETWORK, INC.
UNSECURED CREDITORS OF CORAM
RESOURCE NETWORK, INC. AND
CORAM INDEPENDENT PRACTICE
ASSOCIATION, INC.

By: /s/ SCOTT SHAFER                                         By: /s/ HOBART G. TRUESDELL
   -----------------------------------------                    --------------------------------------------
Name:  Scott Shafer                                             Hobart G. Truesdell,
Title: Co-Chairman                                              Chief Restructuring Officer
                                                                Coram Resource Network, Inc. and Coram
                                                                Independent Practice Association, Inc.

ARLIN M. ADAMS                                               CORAM HEALTHCARE CORP.

 /s/ ARLIN M. ADAMS                                          By: /s/ ARLIN M. ADAMS
--------------------------------------------                    --------------------------------------------
Arlin M. Adams, as Chapter 11 Trustee of                        Arlin M. Adams, Chapter 11 Trustee of
Coram Healthcare Corp. and Coram, Inc.                          Coram Healthcare Corp. and Coram, Inc.

CORAM, INC.

By: /s/ ARLIN M. ADAMS
   -----------------------------------------
   Arlin M. Adams, Chapter 11 Trustee of
   Coram Healthcare Corp. and Coram, Inc.
</Table>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]